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Abstract
Background: The objective of the research was to investigate vascular endothelial growth factor (VEGF) levels in
the context of lipid metabolism and amount of yeast-like fungi colonizing the digestive tract in children and
adolescents with type 1 diabetes mellitus (T1DM).
Methods: The study included 45 children with T1DM and 27 age- and sex-matched healthy control subjects. In the
study sample 33 T1DM patients were administered insulin pump therapy and 12 T1DM patients were administered
multiple daily injections with insulin pen devices. All T1DM patients were free of micro- and macrovascular
complications. In T1DM patients and healthy controls biochemical tests were performed and measurements of
yeast-like fungi colonizing the alimentary tract were conducted. Moreover all study subjects had their serum
VEGF levels measured with ELISA test.
Results: The subgroup of children and adolescents with T1DM and yeast-like fungus colony number 10^3 CFU/g
was shown statistically significantly lower HbA1c levels, and lower but not statistically significantly total cholesterol, LDL
cholesterol and VEGF levels versus T1DM patients with the amount of yeast-like fungi 10^6 CFU/g. Moreover higher
HDL levels were observed in this subgroup versus T1DM patients with the amount of yeast-like fungi 10^6 CFU/g
although the difference was not statistically significant.
Conclusions: Our study has shown no influence of yeast-like fungi on lipid metabolism and VEGF level in children and
adolescents with T1DM. Comprehensive treatment of T1DM patients and intensive insulin therapy with help of
personal insulin pumps can reduce or prevent the development of long-term diabetic complications. Further studies in
this field are needed.
Keywords: Type 1 diabetes mellitus, Children and adolescents, Lipid metabolism, Vascular endothelial growth factor,
Yeast-like fungi
Background
In view of the currently available data hyperglycaemia is
known to be the main factor that contributes to the
development of angiopathic complications in diabetes
[1–3]. Metabolic control of diabetes mellitus is one of
the most important factors, but not the only one, that
affects the risk of long-term angiopathic complications
[4–7]. Several proofs of evidence indicates that the risk
of long-term diabetic complications is increased when
hyperglycaemia is accompanied by lipid metabolism
disorders and high blood pressure values [3, 6, 8]. In our
previous studies we showed a correlation between
systolic blood pressure values and serum levels of vascu-
lar endothelial growth factor (VEGF) in children and
adolescents with type 1 diabetes mellitus (T1DM) [8].
VEGF is a potent mitogenic and chemotactic factor for
endothelial cells, thereby stimulating angiogenesis. VEGF
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can increase vascular permeability, favour oedema and
enhance migration of cells from the circulating blood
into the sites of inflammation. VEGF is an important
factor that triggers inflammatory processes in chronic
diseases [9].
Prevention of long-term complications is among the
most important treatment goals in T1DM patients. All
patients with T1DM have to be monitored for HbA1c
levels, lipid metabolism parameters, blood pressure and
other known risk factors of long-term vascular compli-
cations [5, 10, 11]. Moreover, it must be noticed that
treatment of T1DM children and adolescents has signifi-
cantly changed in Poland and all over the world during
the last decade [12–14]. First of all new insulin therapy
technologies have been developed and implemented,
such as personal insulin pumps integrated with continu-
ous glucose monitoring systems (CGM) [14, 15]. Data
from clinical trials and immunological studies point at
the very important role of even minor blood glucose
fluctuations in the development of both micro- and
macrovascular complications [15–17].
Moreover the role of yeast-like fungi in the course of
diabetes has not been fully elucidated [18–20]. Antigens
found in the human body trigger mechanisms of the
innate and adaptive immune reactions, closely related to
each other. On one hand they can result in elimination
of the causative factor, but on the other hand they can
lead to systemic disorders or even death [21, 22]. Efforts
are being made by our team and other researchers to
investigate the yeast-like fungus virulence and its seque-
lae in T1DM patients [20, 21, 23]. However proving the
causal relationship between infections and development
of complications in T1DM patients remains a big
challenge. In many cases the main problem involves a
long latency time between exposure to the yeast-like
fungus antigen and the occurrence of clinical signs and
symptoms of long-term angiopathic complications [22].
Therefore the aim of our current study was to investigate
VEGF levels in the context of selected lipid metabolism
parameters and the amount of yeast-like fungi colonizing
the alimentary tract of T1DM children and adolescents.
Methods
The study involved 45 adolescent patients (16 girls and
29 boys) with T1DM. Diabetes was diagnosed according
to the Polish Diabetes Association guidelines which
correspond with the guidelines of the WHO [12, 24]. All
T1DM patients were free of micro- and macrovascular
complications. T1DM children and their parents/legal
guardians were provided comprehensive care by diabetes
treatment team composed of diabetologist, nurse, dieti-
cian, psychologist, physiotherapist and educator. In the
study sample 33 T1DM patients were administered
insulin pump therapy and 12 T1DM patients were
administered multiple daily injections with insulin pen
devices. Blood glucose levels were measured by conti-
nous glicemic monitoring systems (CGMS) using an
electrode compatible with “Guardian” device or Medtro-
nic insulin pump (Medtronic Minimed, Northridge,
CA). Glycated haemoglobin (HbA1c) was measured with
an immunoturbidometric method using a Unimate 3 set
(Hoffmann-La Roche AG, Basel, Switzerland). Reference
values for healthy people estimated by the local laboratory
ranged from 4.3 to 5.7% (35–42 mmol/mol). The urinary
albumin was measured by immunoturbidometric assay
using Tina-quant kit (Boehringer Mannheim GmbH,
Germany). Microalbuminuria was diagnosed when in at
least two out of three urine samples daily albumin
excretion was between 30 and 300 mg/24 h, collected
within 6 months from patients with well controlled dia-
betes with no clinical or laboratory signs of ketoacido-
sis. Serum total cholesterol, low density lipoprotein (LDL)
and high density lipoprotein (HDL) cholesterol levels were
assayed by the ARCHITECT cSystem and AEROSET,
Abbott, Wiesbaden, Germany. Lipid profile was assessed
according to the value [25]. Blood pressure was measured
using a 24-h blood pressure monitoring (ABPM) method.
Various sizes of the cuff were used according to age, weight
and arm circumference of the studied subjects. All the
ABPM results, which had less than 80% of technically
correct measurements were excluded from the study.
Threshold values defining range of normal blood pressure
values, pre-hypertension and hypertension state were
according to the centile tables which took into the consid-
eration the gender, age and height centile. Arterial hyper-
tension was diagnosed when mean ABPM values were
above the 95th centile for the corresponding age, gender
and height on at least three separate measurements [26].
In order to enumerate yeast-like fungal colonies in 1 g
faeces, quantitative cultures on Sabouraud Dextrose Agar
were used. The tested materials were fresh faecal samples
from T1DM children and healthy control subjects. The
samples were collected to sterile containers and subjected to
further test procedures. Faecal suspensions in normal saline
in serial dilutions 1:10, 1:100, 1:1000, 1:10,000 were prepared
and incubated for 72 h at 37 °C. According to the number
of colony forming units grown in 1 g faeces the following
index values for the fungus growth were established: from 0
to 10^3 CFU/g and from more than 10^3 to 10^6 CFU/g.
Patients with T1DM and their matched controls were
examined by a pediatrician on the day of collection of
the faecal samples. Medical history was taken and physi-
cal examination was performed and did not reveal any
gastrointestinal complaints in either study group. More-
over the study participants had not been receiving anti-
biotics for up to 3 months prior participation to the study.
Children with symptoms of infection or systemic somatic
illness other than diabetes mellitus were excluded from
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the study. The study patients with T1DM were divided
into two subgroups: with duration of diabetes ≤5 years
and those with disease duration >5 years.
Control group consisted of 27 healthy children and ad-
olescents, age and BMI matched (13 girls and 14 boys).
Written informed consent was obtained from all chil-
dren and adolescents participating in the study, or from
their parent or guardian. The study was approved by the
Ethics Committee of the Medical University of Gdańsk
(no NKBBN/125/2014) and the investigation was carried
out in accordance with the principles of the Declaration
of Helsinki as revised in 1996.
Serum level of VEGF
Serum level of vascular endothelial growth factor was mea-
sured by immunoenzyme ELISA method (Quantikine High
Sensitivity Human by R&D System, Minneapolis, Minn.,
USA) according to manufacturer protocol. Minimum detect-
able concentrations were determined by the manufacturer
as 5.0 pg/ml. Intra-assay was 53.7 and inter-assay 910 preci-
sion performance of the assay were determined on 20 repli-
cates from the quality control data of the laboratory.
Statistical analysis
Statistical analyses were performed with the RKWard
Data Analysis Tool Version 0.6.1 using the KDE Develop-
ment Platform 4.13.3 [27]. The Shapiro-Wilk’s test was
used to evaluate normality of variables. The differences be-
tween the groups were calculated with T Student’s or the
non- parametric U Mann Whitney tests. In all analyses a
two-tailed significance level <0.05 was regarded as statisti-
cally significant. A univariate and multivariate logistic for-
ward regression analysis was used to assess the association
between VEGF and clinical parameters and yeast-like fungal
colonies in 1 g faeces with p < 0.05 for entry.
Results
Clinical characteristics of the study participants
The study involved 45 children and adolescent with T1DM
aged 9.2 +/− 3.6 years, and 27 healthy children and adoles-
cents, age range 9.8 +/− 4.5 years. The group of patients
with T1DM showed significantly higher HbA1c levels p =
0.005, albumin excretion rate p = 0.007 and VEGF p = 0.001
versus control subjects. No significant differences were seen
in age p = 0.65, BMI p = 0.59, total cholesterol p = 0.214,
LDL-cholesterol p = 0.214 and HDL-cholesterol levels p =
0.098 versus healthy control subjects. Clinical characteris-
tics of the studied patients with T1DM as well as the con-
trol healthy subjects are presented in Table 1.
Clinical characteristics of T1DM patients according to
their disease duration
The subgroup of T1DM patients with duration of
diabetes ≤5 years was statistically significantly younger,
p = 0.03, and achieved optimal metabolic control, p = 0.01,
versus T1DM patients with duration of diabetes >5 years.
Moreover T1DM patients with disease duration ≤5 years
were found lower total cholesterol level, p = 0.49, lower
LDL level, p = 0.56, and lower VEGF level, p = 0.37,
although none of these differences was statistically signifi-
cant. Patients with shorter duration of diabetes were
found statistically significantly higher HDL cholesterol
levels versus T1DM patients with disease duration >5 years
(Table 2).









Age (years) 9.2 +/− 3.6 9.8 +/− 4.5 p = 0.65
Duration of diabetes
(years)
5.0+/− 3.0 ——— ————
HbA1c % 7.7 ± 1.24 4.2 ± 0.7 P = 0.005*
BMI (kg/m2) 21.3 ± 1.9 20.2 ± 1.4 P = 0.59
Albumin excretion rate
(mg/24 h)
13.2 ± 7.4 3.75 ± 0.85 p = 0.007*
Total cholesterol (mg/dl) 176.53 ± 26.9 174.3 ± 32.7 p = 0.089
LDL-cholesterol (mg/dl) 103.8 ± 22.07 95.0 ± 30.6 p = 0.214
HDL-cholesterol (mgl/dl) 54.28 ± 11.38 58.6 ± 13.1 p = 0.098
Systolic blood pressure
(mmHg)
113.0 ± 10.0 110.0 ± 9.0 p = 0.64
Diastolic blood pressure
(mmHg)
70.0 ± 9.0 67.0 ± 8.0 p = 0.58
VEGF (pg/ml) 324.54 ± 185.61 120.45 ± 38.50 p = 0.001*
The results are presented as ± SD, significance (p <0.05)
Abbreviations: T1DM diabetes mellitus type 1, BMI body mass index, LDL Low-
density lipoprotein cholesterol, HDL High-density lipoprotein cholesterol, SBP
systolic blood pressure, DBP diastolic blood pressure, VEGF vascular endothelial
growth factor
*Patients with T1DM vs healthy control subjects
Table 2 Clinical characteristics of T1DM patients according to their disease duration
Duration of diabetes Age (years) HbA1c (%) VEGF (pg/ml) Total cholesterol (mg/dl) LDL-cholesterol (mg/dl) HDL-cholesterol (mg/dl)
<=5 years n = 31 10 ± 4.0 7.0 ± 1.2 316.5 ± 21.7 172.1 ± 23.4 99.1 ± 17.1 61.12 ± 8.3
>5 years n = 14 13 ± 2.0 8.1 ± 0.9 389.4 ± 23.8 175.2 ± 25.4 105.6 ± 20.1 53.4 ± 12.9
p-value 0.03* 0.01* 0.37 0.49 0.56 0.02*
The results are presented as ± SD, significance (p <0.05)
Abbreviations: VEGF vascular endothelial growth factor, LDL Low-density lipoprotein cholesterol, HDL High-density lipoprotein cholesterol
*Patients with < =5 years vs >5 years duration of diabetes
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Clinical characteristics of T1DM patients according to the
amount of yeast-like fungi colonizing the digestive tract
The subgroup of children and adolescents with T1DM
and yeast-like fungus colony number 10^3 CFU/g was
shown statistically significantly lower HbA1c levels, p =
0.01, lower but not statistically significantly total
cholesterol and LDL cholesterol levels and lower but not
statistically significantly VEGF levels versus T1DM pa-
tients with the amount of yeast-like fungi 10^6 CFU/g.
Moreover higher HDL levels were observed in this sub-
group versus T1DM patients with the amount of yeast-
like fungi 10^6 CFU/g, p = 0.41, although the difference
was not statistically significant (Table 3).
Investigation of relationship between duration of
diabetes and clinical parameters in T1DM patients
In T1DM children a positive but statistically insignifi-
cant correlation was seen between duration of diabetes
and VEGF levels; Rs = 0.113, p = 0.44 (Fig. 1).
Investigation of relationship between serum VEGF levels
and lipid profile in T1DM children and adolescents
In the group of T1DM children a positive but statisti-
cally insignificant correlation was seen between serum
VEGF and total cholesterol levels, Rs = 0.105, p = 0.459
(Fig. 2a), and between VEGF and LDL cholesterol levels,
Rs = 0.005, p = 0.973 (Fig. 2b). A negative, but statistically
insignificant correlation was found between VEGF and
HDL-cholesterol levels, Rs = 0.002, p = 0.988 (Fig. 2c).
In the next step of the research logistic regression ana-
lysis was conducted and showed no effect of HbA1c and
lipid profile on VEGF levels in T1DM patients (Table 4).


















Fig. 1 Correlation between serum VEGF level and duration of diabetes
in T1DM patients














































































Fig. 2 a Correlation between serum VEGF and total cholesterol levels in T1DM patients. b Correlation between serum VEGF and LDL-cholesterol
levels in T1DM patients. c Correlation between serum VEGF and HDL-cholesterol levels in T1DM patients
Table 3 Clinical characteristics of T1DM patients according to the amount of yeast-like fungi colonizing the digestive tract
Yeast–like
fungi
HbA1c % Total cholesterol (mg/dl) LDL-cholesterol (mg/dl) HDL-cholesterol (mg/dl) VEGF (pg/ml)
10^3 CFU/g
n = 19
7.1 ± 0.8 172.81 ± 29.33 101.87 ± 23.65 59.4 ± 8.3 327.03 ± 179.9
10^6 CFU/g
n = 26
7.4 ± 1.9 183.52 ± 20.89 107.41 ± 18.89 51.6 ± 12.4 370.37
± 194.84
p-value 0.01* 0.14 0.23 0.41 0.32
The results are presented as ± SD, significance (p < 0.05)
Abbreviations: VEGF vascular endothelial growth factor, LDL Low-density lipoprotein cholesterol, HDL High-density lipoprotein cholesterol
*Patients with T1DM and yeast-like fungi 10^3 CFU/g vs 10^6 CFU/g
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Discussion
Our previous studies and studies by other authors have
shown that long-term diabetic complications occur after
5 years of the disease [1, 4, 8]. Therefore for the purpose
of analyses the study patients with T1DM were divided
into two subgroups: patients with duration of diabetes
≤5 years and those with disease duration >5 years. In our
study the subgroup of T1DM children and adolescents
with duration of diabetes ≤5 years and HbA1c level (7.0 +
1.2%) did not show any significant differences in total
cholesterol and LDL cholesterol levels versus T1DM
patients with disease duration >5 years and HbA1c (8.1 +
0.9%). Higher HDL cholesterol levels were seen in T1DM
children with disease duration <5 years and HbA1c =
7.0 + 1.2% versus T1DM patients with disease duration
>5 years and HbA1c = 8.1 + 0.9%. Currently available data
on lipid metabolism in T1DM patients are not unanimous
[6, 28–30]. Recently, unexpected results have been pre-
sented by Klein et al., who studied 730 patients for
24 years, each patient having been tested four times, and
did not show any relationship between increased serum
levels of oxidized low-density lipoprotein and frequency of
macular oedema or diabetic retinopathy severity in T1DM
patients [28]. In other studies the authors pointed at lipid
profile abnormalities in patients with disease duration
longer than 5 years, with poor metabolic control and
cardiovascular complications [6, 29, 30].
In our study no significant differences in serum levels
of VEGF were detected in patients with T1DM and
duration of diabetes ≤5 years versus T1DM patients with
disease duration of >5 years. In T1DM children a statis-
tically insignificant correlation was seen between VEGF
levels and duration of diabetes, total cholesterol and
LDL cholesterol levels. This lack of correlation between
VEGF serum levels and lipid metabolism or HbA1c
levels can be partly explained by improved methods of
insulin therapy in T1DM patients and partly by anti-
inflammatory effects of HDL cholesterol.
Our results are in agreement with other authors who
found a negative correlation between serum VEGF, CRP
and HDL cholesterol levels in T1DM insulin pump
patients [31]. The authors suggested that insulin pump
therapy could result in considerably higher HDL choles-
terol levels which could reduce both CRP and VEGF
levels. The continuous insulin infusion with insulin
pump in T1DM patients is likely to prevent atheroscler-
osis progression, thereby reducing the risk of cardiovas-
cular disease [31]. Admittedly, our previous studies and
studies conducted by other authors showed statistically
significantly higher serum VEGF levels in children and
adolescents with T1DM [32–35]. However the studied
group of T1DM children and adolescents was older,
showed poor metabolic control and had clinically overt
diabetic retinopathy (DR), nephropathy and arterial hyper-
tension [8, 32–35]. In our present study T1DM patients
were free of long-term diabetic complications and had
shorter history of diabetes and lower HbA1c levels.
In the end step of the study the effect of yeast-like
fungi on lipid profile and VEGF levels was investigated.
In the studied group of T1DM children and adolescents
with the amount of yeast-like fungi 10^3 CFU/g signifi-
cantly lower HbA1c levels were seen as well as lower
total cholesterol, LDL cholesterol and lower serum
VEGF levels versus T1DM patients with the amount of
yeast like fungi colonizing the alimentary tract 10^6
CFU/g. We suggest, that in patients with a short history
of diabetes of <5 years and good metabolic control as
well as normal lipid profile the prevalence of the yeast-
like fungi in the digestive tract is not significantly in-
creased. This could be related to the fact that children
had not complained of any gastrointestinal problems
and had not been treated with any antibiotics for up to
3 months prior to their faecal sample collection. What’s
more, about 75% of T1DM patients were administered
insulin therapy with insulin pumps integrated with con-
tinuous glucose monitoring systems. It must be empha-
sized that children with T1DM are currently achieving
HbA1c target levels more and more frequently thanks to
the use of personal insulin pumps integrated with continu-
ous glucose monitoring systems [13–15]. T1DM children
and their parents and/or legal guardians were provided with
comprehensive care educator. Education motivates patients
to respond to the challenges of insulin therapy, eliminates
stress and prevents anxiety about the future [10].
Conclusions
Our study has shown no relationship between serum
VEGF levels and lipid metabolism and no influence of
yeast-like fungi on VEGF levels in T1DM patients. Com-
prehensive treatment of T1DM patients and intensive
insulin therapy with help of personal insulin pumps can
reduce or prevent the development of long-term diabetic
complications. Further studies in this field are needed.
Abbreviations
BMI: Body mass index; CGMS: Continous glicemic monitoring systems;
DBP: Diastolic blood pressure; DR: Diabetic retinopathy; DV: Dependent
Table 4 Logistic regression analysis results for the influence of
Hb1A and lipid levels on VEGF levels in T1DM patients
DV : VEGF β p-value
HbA1c 31.761001 0.704




Abbreviations: DV dependent variable, β standard coefficient of regression,
VEGF vascular endothelial growth factor, LDL Low-density lipoprotein cholesterol,
HDL High-density lipoprotein cholesterol
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reactive protein; LDL: Low-density lipoprotein cholesterol; SBP: Systolic blood
pressure; T1DM: Type 1 diabetes mellitus; VEGF: Vascular endothelial growth factor
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